Normal cells, but not cancer cells, survive severe Plk1 depletion.
about
Computational analysis of phosphopeptide binding to the polo-box domain of the mitotic kinase PLK1 using molecular dynamics simulationPolo-like kinase 3 is required for entry into S phasePhosphorylation by polo-like kinase 1 induces the tumor-suppressing activity of FADDCell division cycle 6, a mitotic substrate of polo-like kinase 1, regulates chromosomal segregation mediated by cyclin-dependent kinase 1 and separaseInhibitory role of Plk1 in the regulation of p73-dependent apoptosis through physical interaction and phosphorylationMyosin phosphatase-targeting subunit 1 regulates mitosis by antagonizing polo-like kinase 1Plk1-mediated phosphorylation of Topors regulates p53 stabilityPLK-1 Targeted Inhibitors and Their Potential against TumorigenesisA high-content small molecule screen identifies sensitivity of glioblastoma stem cells to inhibition of polo-like kinase 1The Plk1 inhibitor BI 2536 temporarily arrests primary cardiac fibroblasts in mitosis and generates aneuploidy in vitroThe Functional Significance of Posttranslational Modifications on Polo-Like Kinase 1 Revealed by Chemical Genetic ComplementationStructure of theBrachydanio rerioPolo-like kinase 1 (Plk1) catalytic domain in complex with an extended inhibitor targeting the adaptive pocket of the enzymePolo-like kinase and its inhibitors: Ready for the match to start?Microenvironmental influence on pre-clinical activity of polo-like kinase inhibition in multiple myeloma: implications for clinical translationA series of beta-carboline derivatives inhibit the kinase activity of PLKsIdentification of Polo-like kinase 1 interaction inhibitors using a novel cell-based assayMultiple cancer testis antigens function to support tumor cell mitotic fidelity.Transcriptional activity of c-Jun is critical for the suppression of AR function.Distinct pools of cdc25C are phosphorylated on specific TP sites and differentially localized in human mitotic cellsChemical genetics reveals the requirement for Polo-like kinase 1 activity in positioning RhoA and triggering cytokinesis in human cells.Use of the novel Plk1 inhibitor ZK-thiazolidinone to elucidate functions of Plk1 in early and late stages of mitosis.Cancer biomarker discovery: the entropic hallmark.Protein tyrosine phosphatase Shp2 (Ptpn11) plays an important role in maintenance of chromosome stabilitySmall interfering RNA library screen of human kinases and phosphatases identifies polo-like kinase 1 as a promising new target for the treatment of pediatric rhabdomyosarcomas.Elevated levels of the polo kinase Cdc5 override the Mec1/ATR checkpoint in budding yeast by acting at different steps of the signaling pathway.Targeted depletion of Polo-like kinase (Plk) 1 through lentiviral shRNA or a small-molecule inhibitor causes mitotic catastrophe and induction of apoptosis in human melanoma cells.Combinatorial inhibition of Plk1 and PKCβ in cancer cells with different p53 statusSynergistic interactions between PLK1 and HDAC inhibitors in non-Hodgkin's lymphoma cells occur in vitro and in vivo and proceed through multiple mechanismsMELK is an oncogenic kinase essential for mitotic progression in basal-like breast cancer cells.Polo-like kinase 1 enhances survival and mutagenesis after genotoxic stress in normal cells through cell cycle checkpoint bypass.RNAi screen identifies a synthetic lethal interaction between PIM1 overexpression and PLK1 inhibitionProteins ZNF198 and SUZ12 are down-regulated in hepatitis B virus (HBV) X protein-mediated hepatocyte transformation and in HBV replicationRegulatory functional territory of PLK-1 and their substrates beyond mitosis.Inhibition of Polo kinase by BI2536 affects centriole separation during Drosophila male meiosis.Time-resolved human kinome RNAi screen identifies a network regulating mitotic-events as early regulators of cell proliferation.Plk1-targeted small molecule inhibitors: molecular basis for their potency and specificity.Beyond taxanes: a review of novel agents that target mitotic tubulin and microtubules, kinases, and kinesins.Inhibition of polo-like kinase 1 (Plk1) enhances the antineoplastic activity of metformin in prostate cancer.Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy.Polo-like kinase 1 activated by the hepatitis B virus X protein attenuates both the DNA damage checkpoint and DNA repair resulting in partial polyploidy
P2860
Q21092524-DEC16E74-51A2-497A-BC78-01D36591D428Q24294896-1F5E9E76-45D1-4AD3-AB81-0D70A9626D81Q24301769-88A023B8-6D00-4B82-BE6C-7A8352FBC643Q24305189-319BCADA-7ACC-411C-98E8-D09425EF85A8Q24305405-DB7F991B-AE52-4BB3-BB66-C4721F2D35D5Q24312184-772DFD79-B865-46B2-9BE4-96ECDA683E1FQ24314588-ADB1D6E3-576B-438D-99A7-E910A8093D9AQ26777811-22BE24DF-E2FC-4B19-A11E-2B31781E4DE6Q27304385-95FDA534-8D90-47CA-87CE-016CE768A48CQ27319063-79F911DD-B1C3-4E20-B897-9CD08F223AA6Q27320051-9C2457C6-EF4C-41D6-9EFD-662F0517F6E0Q27651416-5358D4FF-2FC9-4A22-A42F-028AE47BB6C6Q28087433-6E808D66-8322-4635-BA1E-2AFF27D96CBBQ28478937-E179C0AE-F1C0-4967-9886-6DF4A900FDB8Q28484219-F759402A-9DFB-4281-8F02-19E2CF8D2AE8Q28820936-3F4A9EDF-7851-4DC2-94E0-3D9B09A0C5BEQ29871492-93D4531F-0F04-4E12-A7D8-68CA8B4E0F23Q30412500-5B468E0D-7F84-42B9-879F-23A586EB5C26Q30435385-AAA45C65-56C5-413B-AC11-6A6A3533CA59Q30479187-64BDF430-0679-477B-A7BA-A53E76F2E2D5Q30480149-441F236B-BFFC-42F9-93D6-FBD73C994407Q30496149-80BC60F4-544B-4A82-8954-E1453C0F476BQ30525672-F274D9BF-C774-4269-9FFD-7292EB559EB6Q33514778-62D71975-0A3C-409B-9207-31DAC73E7F7BQ33526233-0D01AC62-B411-45E5-A789-E6A33694421BQ33564389-EAB07B85-DA32-42D4-9F90-9C3B32B1E2CFQ33688600-B321BA0E-3877-4A12-9C18-7FEFC523C05BQ33761796-013DC53A-3BCB-4394-A29F-6FCBD2742E43Q33762222-E004B664-3B7B-4E09-889D-BE833816B2BFQ33829178-01E96837-91DF-4CA5-93EB-D35BE59BDE2CQ33861057-7CCE6BF7-76AC-4EE0-87D3-19F64E9B0FD2Q33867835-BCA39A3D-7CA6-4C64-BFE6-5002DAB43334Q33914204-675D7A0D-592F-45C7-A005-5E4537DBA97CQ33952881-1753750B-0E4E-445C-B8D6-14C2B69BD732Q33963929-BF9D8C47-EF0D-4092-9D3C-52F7B6B1B01CQ33978551-FD9ADC5E-F88D-4FDD-9B6B-B577FEEE5537Q33999018-C505D16C-8277-4193-8C62-096DD5403A65Q34042731-E4B3548A-9615-4E21-8C85-818B57899584Q34106830-49BE7EBF-AA09-4D5B-8BB4-06376EF094A7Q34144573-65CD4E13-ED7A-4E11-BE8D-087602B9BEEF
P2860
Normal cells, but not cancer cells, survive severe Plk1 depletion.
description
2006 nî lūn-bûn
@nan
2006 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի մարտին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Normal cells, but not cancer cells, survive severe Plk1 depletion.
@ast
Normal cells, but not cancer cells, survive severe Plk1 depletion.
@en
Normal cells, but not cancer cells, survive severe Plk1 depletion.
@nl
type
label
Normal cells, but not cancer cells, survive severe Plk1 depletion.
@ast
Normal cells, but not cancer cells, survive severe Plk1 depletion.
@en
Normal cells, but not cancer cells, survive severe Plk1 depletion.
@nl
prefLabel
Normal cells, but not cancer cells, survive severe Plk1 depletion.
@ast
Normal cells, but not cancer cells, survive severe Plk1 depletion.
@en
Normal cells, but not cancer cells, survive severe Plk1 depletion.
@nl
P2093
P2860
P1476
Normal cells, but not cancer cells, survive severe Plk1 depletion.
@en
P2093
Raymond L Erikson
Xiaoqi Liu
P2860
P304
P356
10.1128/MCB.26.6.2093-2108.2006
P407
P577
2006-03-01T00:00:00Z